NCT00266344已完成2 期
MK0928 Phase IIb Dose-range Finding Study -Primary Insomnia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 520
- 主要终点
- Patient-reported total sleep time.
研究概览
简要总结
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of primary insomnia
排除标准
- •Patients with an active psychiatric disorder other than primary insomnia
结局指标
主要结局
Patient-reported total sleep time.
次要结局
- Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening.
研究者
相似试验
终止
2 期
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)Primary InsomniaNCT00266357H. Lundbeck A/S50
已完成
3 期
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)InsomniaNCT00103818H. Lundbeck A/S900
已完成
3 期
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)InsomniaNCT00095069H. Lundbeck A/S600
已完成
3 期
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)InsomniaNCT00095043H. Lundbeck A/S320
已完成
2 期
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)SchizophreniaNCT04624243Merck Sharp & Dohme LLC499